Clinical Trial Update: A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis [Phase 2]

View source ↗

Summary

Phase 2 safety study of BBI-4000 Gel in pediatric patients with primary axillary hyperhidrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axillary Hyperhidrosis

Drugs mentioned

• BBI-4000 Gel

Snippet

Sponsor: Botanix Pharmaceuticals | Conditions: Primary Axillary Hyperhidrosis | Phase 2 | Status: COMPLETED | Results posted: 2023-03-14